Ratings changes for Nebius Group, Okta, Credo Technology Group, Seacoast Banking Corporation of Florida, Tempus AI, Credo Technology Group, Seagate Technology and more...Upgrade to MarketBeat All Access to get our best stock ideas, proprietary research, portfolio monitoring tools, and more. Start Your Free Trial.

June 2nd, 2026

The CBDC Timeline Has Leaked (BofA) (Ad)

Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.

Watch how to access the legal backdoor before it closes.

Today's Top Stories

How the Latest Federal Contract Boosts D-Wave's Prospects

By Nathan Reiff | June 2, 2026 09:40 AM

The chipmaker 148 times smaller than NVIDIA supplying Musk (Ad)

By Brownstone Research

Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence?

By Ryan Hasson | June 2, 2026 09:05 AM

MGM Buyout: The House Doesn't Always Win

By Jeffrey Neal Johnson | June 2, 2026 08:30 AM

SpaceX’s New ‘Dark Energy’ Division (Ad)

By Altimetry

Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?

By Ryan Hasson | June 2, 2026 07:20 AM

Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors

By Chris Markoch | June 2, 2026 06:45 AM

Quick Links

Analyst Ratings My MarketBeat Account Settings MarketBeat All Access Stock Lists Stock Screener Calculators Premium Reports Best Stocks to Buy in June

BNZI posted 169 percent revenue growth - is a turnaround forming

BNZI - where explosive SaaS growth meets a potential bottom signal (Ad)

Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, with Q4 growth of 116% and gross margins expanding to 81.9% - hallmarks of a scalable SaaS model gaining traction.
With over 150,000 customers, a planned acquisition of ConnectAndSell expected to add roughly $15 million in annual revenue, and a fresh Zacks Rank No. 2 Buy upgrade, institutional confidence is building. A hammer candlestick pattern also suggests potential selling exhaustion and a possible bottom formation.

Discover why BNZI is drawing attention as a small-cap AI turnaround play

Analysts' Upgrades

Abivax (NASDAQ:ABVX) was upgraded by Wedbush from "underperform" to "neutral". They now have a $90.00 price target on the stock, down from $110.00. This represents a 13.9% upside from the current price of $79.04.

Eagle Materials (NYSE:EXP) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral". They now have a $225.00 price target on the stock. This represents a 2.0% upside from the current price of $220.55.

Hewlett Packard Enterprise (NYSE:HPE) was upgraded by Loop Capital from "hold" to "buy". They now have a $75.00 price target on the stock. This represents a 26.6% upside from the current price of $59.24.

Knight-Swift Transportation (NYSE:KNX) was upgraded by Susquehanna from "neutral" to "positive". They now have a $90.00 price target on the stock. This represents a 16.4% upside from the current price of $77.31.

View More Upgrades

One of Nevada's Most Overlooked Gold Plays Just Got a Lot More Interesting (Ad)

Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Central banks bought a record 863 tonnes in 2025 alone - and one small-cap explorer in Nevada's Walker Lane Belt may be positioned to benefit.
Sitting 18 miles north of Tonopah in the same district that produced over 15 million ounces at Kinross Gold's Round Mountain Mine, this explorer carries historic drill intercepts of 30 meters at 2.5 g/t gold and surface samples exceeding 100 g/t. With a market cap under $15 million and drills ready to turn in H2 2026, the window may be narrow.

Get the full story on this drill-ready Nevada gold explorer

Analysts' Downgrades

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by HC Wainwright from "buy" to "neutral". They now have a $3.00 price target on the stock. This represents a 0.1% upside from the current price of $3.00.

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by Stifel Nicolaus from "buy" to "hold". They now have a $3.00 price target on the stock. This represents a 0.1% upside from the current price of $3.00.

Sociedad Quimica y Minera (NYSE:SQM) was downgraded by JPMorgan Chase & Co. from "overweight" to "neutral". They now have a $100.00 price target on the stock. This represents a 24.6% upside from the current price of $80.25.

View More Downgrades

Why Rare Earths Are Suddenly Back in Focus (Ad)

Rare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - yet they've stayed largely out of the spotlight. The International Energy Agency projects multi-fold demand growth over the coming decades, while processing remains tightly concentrated.
One North American company is already expanding into rare earths while still early, still building, and still not widely followed. As capital begins to follow attention, early-stage positioning may matter more than ever.

Explore the company expanding into rare earths while it's still early

Analysts' New Coverage

GRAIL (NASDAQ:GRAL) is now covered by Wolfe Research. They set a "peer perform" rating on the stock. The current price is $60.32.

Guardant Health (NASDAQ:GH) is now covered by Wolfe Research. They set an "outperform" rating and a $150.00 price target on the stock. This represents a 16.1% upside from the current price of $129.18.

Mettler-Toledo International (NYSE:MTD) is now covered by Wolfe Research. They set a "peer perform" rating on the stock. The current price is $1,174.80.

Mirum Pharmaceuticals (NASDAQ:MIRM) is now covered by Citigroup Inc.. They set a "buy" rating and a $145.00 price target on the stock. This represents a 54.2% upside from the current price of $94.04.

Mobia Medical (NASDAQ:MOBI) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $15.00 price target on the stock. This represents a 11.1% upside from the current price of $13.50.

Mobia Medical (NASDAQ:MOBI) is now covered by Bank of America Corporation. They set a "buy" rating and a $16.00 price target on the stock. This represents a 18.5% upside from the current price of $13.50.

Mobia Medical (NASDAQ:MOBI) is now covered by BTIG Research. They set a "buy" rating and a $19.00 price target on the stock. This represents a 40.7% upside from the current price of $13.50.

Natera (NASDAQ:NTRA) is now covered by Wolfe Research. They set an "outperform" rating and a $260.00 price target on the stock. This represents a 21.0% upside from the current price of $214.87.

Nebius Group (NASDAQ:NBIS) is now covered by BNP Paribas Exane. They set a "neutral" rating and a $255.00 price target on the stock. This represents a 4.1% downside from the current price of $265.99.

Neurocrine Biosciences (NASDAQ:NBIX) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $213.00 price target on the stock. This represents a 35.3% upside from the current price of $157.47.

Nutex Health (NASDAQ:NUTX) is now covered by Lake Street Capital. They set a "buy" rating and a $235.00 price target on the stock. This represents a 82.8% upside from the current price of $128.57.

Odyssey Therapeutics (NASDAQ:ODTX) is now covered by Wedbush. They set an "outperform" rating and a $30.00 price target on the stock. This represents a 76.9% upside from the current price of $16.96.

Odyssey Therapeutics (NASDAQ:ODTX) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $26.00 price target on the stock. This represents a 53.3% upside from the current price of $16.96.

Odyssey Therapeutics (NASDAQ:ODTX) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $40.00 price target on the stock. This represents a 135.8% upside from the current price of $16.96.

Repligen (NASDAQ:RGEN) is now covered by Wolfe Research. They set an "outperform" rating and a $145.00 price target on the stock. This represents a 19.6% upside from the current price of $121.21.

Revvity (NYSE:RVTY) is now covered by Wolfe Research. They set a "peer perform" rating on the stock. The current price is $100.24.

Stevanato Group (NYSE:STVN) is now covered by Wolfe Research. They set an "outperform" rating and a $21.00 price target on the stock.

Take-Two Interactive Software (NASDAQ:TTWO) is now covered by Piper Sandler. They set an "overweight" rating and a $280.00 price target on the stock. This represents a 27.8% upside from the current price of $219.12.

Tempus AI (NASDAQ:TEM) is now covered by Wolfe Research. They set a "peer perform" rating on the stock. The current price is $50.82.

Thermo Fisher Scientific (NYSE:TMO) is now covered by Wolfe Research. They set an "outperform" rating and a $535.00 price target on the stock. This represents a 9.8% upside from the current price of $487.21.

Unity Software (NYSE:U) is now covered by Piper Sandler. They set an "overweight" rating and a $40.00 price target on the stock. This represents a 29.0% upside from the current price of $31.01.

Veracyte (NASDAQ:VCYT) is now covered by Wolfe Research. They set an "outperform" rating and a $55.00 price target on the stock. This represents a 16.5% upside from the current price of $47.22.

Veradermics (NYSE:MANE) is now covered by Needham & Company LLC. They set a "buy" rating and a $136.00 price target on the stock. This represents a 35.6% upside from the current price of $100.31.

Victory Capital (NASDAQ:VCTR) is now covered by The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $90.00 price target on the stock. This represents a 5.9% upside from the current price of $85.02.

Waters (NYSE:WAT) is now covered by Wolfe Research. They set an "outperform" rating and a $425.00 price target on the stock. This represents a 13.8% upside from the current price of $373.43.

X4 Pharmaceuticals (NASDAQ:XFOR) is now covered by Leerink Partners. They set an "outperform" rating and a $12.00 price target on the stock. This represents a 188.8% upside from the current price of $4.16.

View More New Coverage

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial